Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosnetupitant with mFOLFIRINOX in unresectable pancreatic cancer
jRCT1061250083Recruiting
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of netupitant + palonosetron in pancreatic cancer (PC). Started Jan 2026; status: recruiting.
02
Drugs
netupitant + palonosetron
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT1061250083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061250083.